BR112013005792A8 - métodos para o tratamento concomitante de teofilina e febuxostat - Google Patents

métodos para o tratamento concomitante de teofilina e febuxostat

Info

Publication number
BR112013005792A8
BR112013005792A8 BR112013005792A BR112013005792A BR112013005792A8 BR 112013005792 A8 BR112013005792 A8 BR 112013005792A8 BR 112013005792 A BR112013005792 A BR 112013005792A BR 112013005792 A BR112013005792 A BR 112013005792A BR 112013005792 A8 BR112013005792 A8 BR 112013005792A8
Authority
BR
Brazil
Prior art keywords
theophylline
febuxostat
concomitant treatment
methods
treatment
Prior art date
Application number
BR112013005792A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013005792A2 (pt
Inventor
Naik Himanshu
Gunawardhana Lhanoo
Tsai Max
Original Assignee
Takeda Pharmaceuticals Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44653592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013005792(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Usa Inc filed Critical Takeda Pharmaceuticals Usa Inc
Publication of BR112013005792A2 publication Critical patent/BR112013005792A2/pt
Publication of BR112013005792A8 publication Critical patent/BR112013005792A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112013005792A 2010-09-10 2011-09-08 métodos para o tratamento concomitante de teofilina e febuxostat BR112013005792A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38148210P 2010-09-10 2010-09-10
PCT/US2011/050870 WO2012033941A1 (en) 2010-09-10 2011-09-08 Methods for concomitant treatment of theophylline and febuxostat

Publications (2)

Publication Number Publication Date
BR112013005792A2 BR112013005792A2 (pt) 2016-05-03
BR112013005792A8 true BR112013005792A8 (pt) 2018-05-08

Family

ID=44653592

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013005792A BR112013005792A8 (pt) 2010-09-10 2011-09-08 métodos para o tratamento concomitante de teofilina e febuxostat

Country Status (11)

Country Link
US (3) US9107912B2 (https=)
EP (1) EP2613780B1 (https=)
JP (1) JP5978216B2 (https=)
KR (1) KR101797936B1 (https=)
CN (1) CN103298466B (https=)
AU (1) AU2011299153B2 (https=)
BR (1) BR112013005792A8 (https=)
CA (1) CA2812034C (https=)
ES (1) ES2532210T3 (https=)
RU (1) RU2013109380A (https=)
WO (1) WO2012033941A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2607953A1 (en) * 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
EP1940397A4 (en) * 2005-08-03 2010-01-20 Takeda Pharmaceuticals North A METHOD FOR TREATING HYPERTONIA
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
EP2101761A4 (en) * 2006-11-13 2010-01-27 Takeda Pharmaceuticals North A METHODS FOR PRESERVING RENAL FUNCTION USING XANTHINE OXYDOREDUCTASE INHIBITORS
CN101646440A (zh) * 2007-01-19 2010-02-10 武田制药北美公司 使用黄嘌呤氧化还原酶抑制剂和抗炎剂预防痛风突发或减少痛风突发次数的方法
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
AU2011299153B2 (en) 2010-09-10 2014-10-30 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
CN103862983B (zh) * 2012-12-12 2016-12-21 石狮市冠鑫反光材料有限公司 3d立体画制作工艺
ES2552706B1 (es) * 2014-05-29 2016-09-13 Universitat De Les Illes Balears La teobromina y sus derivados para el tratamiento o prevenciónde la litiasis renal
KR102133290B1 (ko) * 2018-10-23 2020-07-13 연세대학교 산학협력단 결핵의 예방 또는 치료용 조성물
CN120271528B (zh) * 2025-04-08 2025-08-22 中国食品药品检定研究院 一种非布司他与苦豆碱共无定型物及其制备方法和应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3079303A (en) 1958-12-11 1963-02-26 Smith Kline French Lab Basic tablet granulation and process of using same
US4058614A (en) 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
US4296122A (en) 1975-07-09 1981-10-20 Merck & Co., Inc. 2,3-Dihydro-6,7-disubstituted-5-(acyl)benzofuran-2-carboxylic acids
DE2707270A1 (de) 1977-02-19 1978-08-24 Hoechst Ag Pyrazolo-diazepine und verfahren zu ihrer herstellung
DE2707268A1 (de) 1977-02-19 1978-08-31 Hoechst Ag Indol-3-carbaldehyd-oxime und verfahren zu ihrer herstellung
DE2707269A1 (de) 1977-02-19 1978-08-24 Hoechst Ag Heterocyclische stickstoffverbindungen und verfahren zu ihrer herstellung
DE2727802A1 (de) 1977-06-21 1979-04-19 Hoechst Ag Sulfamoyl-arylketone und verfahren zu ihrer herstellung
JPS5936919B2 (ja) 1978-10-14 1984-09-06 日本新薬株式会社 インド−ル誘導体
DE3112116A1 (de) 1981-03-27 1982-11-04 Mundipharma GmbH, 6250 Limburg "arzneimittel"
US4510322A (en) 1981-07-13 1985-04-09 Merck & Co., Inc. Indacrinone having enhanced uricosuric
DE3232922A1 (de) 1982-09-04 1984-03-08 Hoechst Ag, 6230 Frankfurt Sulfamoylbenzophenon-derivate, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen
US4632930A (en) 1984-11-30 1986-12-30 E. I. Du Pont De Nemours And Company Antihypertensive alkyl-arylimidazole, thiazole and oxazole derivatives
US5047246A (en) 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
JPH0366669A (ja) 1989-08-03 1991-03-22 Shionogi & Co Ltd 複素環式化合物
ES2092580T3 (es) 1990-11-30 1996-12-01 Teijin Ltd Derivado de 2-ariltiazol y composicion farmaceutica que contiene el mismo.
CA2115442C (en) 1991-09-09 2003-09-23 Christopher Franklin Bigge Pharmaceutical preparation containing an uricosuric agent and an excitatory amino acid antagonist
US5358961A (en) 1991-11-30 1994-10-25 Jin Ro Limited Pyrrolidine derivatives
JP2706037B2 (ja) 1993-04-13 1998-01-28 帝人株式会社 シアノ化合物およびその製造方法
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
JPH07242694A (ja) 1994-02-28 1995-09-19 Yamasa Shoyu Co Ltd トリアゾロプリンヌクレオシド誘導体及び該誘導体を製造するのに有用な合成中間体
US5514681A (en) 1994-08-17 1996-05-07 Virginia Tech Intellectual Properties, Inc. Compositions and methods for controlling pest insects
US6037344A (en) 1994-08-17 2000-03-14 Virginia Tech Intellectual Properties, Inc. Compositions and methods for controlling pest insects
US5770601A (en) 1994-08-17 1998-06-23 Virginia Tech Intellectual Properties, Inc. Compositions and methods for controlling pest insects
AUPM835394A0 (en) 1994-09-23 1994-10-13 King, Michael G. Dr. Method for controlling or eliminating the need to smoke tobacco, and for treating ailments which may lead to the said need
US5990118A (en) 1995-02-21 1999-11-23 Yamasa Corporation Purine compounds and xanthine oxidase inhibitors
US6084147A (en) 1995-03-17 2000-07-04 Studsvik, Inc. Pyrolytic decomposition of organic wastes
DE69632854T2 (de) 1995-04-07 2005-07-14 Teijin Ltd. Schutzmittel für Organe und Gewebe
JPH1045773A (ja) 1996-08-07 1998-02-17 Daicel Chem Ind Ltd リン含有化合物およびその製造方法
ID21775A (id) 1996-10-25 1999-07-22 Yoshitomi Pharmaceutical Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya
US5965625A (en) 1997-03-21 1999-10-12 King; Michael Glenn Compositions and methods for the control of smoking
JPH11140086A (ja) 1997-11-07 1999-05-25 Yamasa Shoyu Co Ltd ４−置換−１Ｈ−６−オキソピラゾロ［３，４−ｄ］ピリミジン化合物及びキサンチンオキシダーゼ阻害剤
AU1520699A (en) 1997-11-07 1999-05-31 Johns Hopkins University, The Methods for treatment of disorders of cardiac contractility
CA2566652C (en) 1998-06-19 2008-10-21 Teijin Limited Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof
RU2246318C2 (ru) 1998-08-06 2005-02-20 Маунтэн Вью Фармасьютикэлз, Инк. Конъюгаты peg-уриказы и их использование
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
US6372246B1 (en) 1998-12-16 2002-04-16 Ortho-Mcneil Pharmaceutical, Inc. Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals
US6281222B1 (en) 1999-08-19 2001-08-28 Inotek Corporation Compositions and method for treatment of acetaminophen intoxication
ECSP993280A (es) 1999-12-17 2001-07-27 Polimorfos de acido 2- (3- ciano -4 -isobutiloxi fenil) -4 -metil -5-tiazol carboxilico y metodo de produccion de los mismos
EP1317258B1 (en) 2000-06-28 2009-02-11 Merck & Co., Inc. Use of allopurinol for the treatment of hypertension
JP2002105067A (ja) 2000-09-28 2002-04-10 Teijin Ltd ２−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物
ITMI20010206A1 (it) 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
WO2002085381A1 (en) 2001-04-18 2002-10-31 Genzyme Corporation Method for treating gout and binding uric acid
WO2002085380A1 (en) 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for treating gout and reducing serum uric acid
JP2005507932A (ja) 2001-10-12 2005-03-24 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満の処置のためのフェニル置換５−員窒素含有複素環
CA2462132C (en) 2002-01-28 2010-08-10 Fuji Yakuhin Co., Ltd. 1,2,4-triazole compounds
WO2003082279A1 (en) 2002-03-28 2003-10-09 Teijin Limited Solid preparation containing single crystal form
US20060040945A1 (en) 2002-05-17 2006-02-23 Merckle Gmbh Annellated pyrrole compounds as proton pump inhibitors for treating ulcer
US7078423B2 (en) 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
US20040122067A1 (en) 2002-12-20 2004-06-24 Lin Zhao Treatment of chronic heart failure
US20040131676A1 (en) 2002-12-20 2004-07-08 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20040121004A1 (en) 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
WO2005018635A2 (en) 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
WO2006028342A1 (en) 2004-09-06 2006-03-16 Biosynergen, Inc. A novel xanthine oxidase inhibitor and a pharmaceutical composition containing the same
WO2006055412A1 (en) 2004-11-19 2006-05-26 Shiva Biomedical, Llc Methods of treating erythropoietin-resistance
CA2607953A1 (en) 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
EP1940397A4 (en) 2005-08-03 2010-01-20 Takeda Pharmaceuticals North A METHOD FOR TREATING HYPERTONIA
CA2630639A1 (en) 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Treatment of qt interval prolongation and diseases associated therewith
US20090124623A1 (en) 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
EP2101761A4 (en) 2006-11-13 2010-01-27 Takeda Pharmaceuticals North A METHODS FOR PRESERVING RENAL FUNCTION USING XANTHINE OXYDOREDUCTASE INHIBITORS
CN101646440A (zh) 2007-01-19 2010-02-10 武田制药北美公司 使用黄嘌呤氧化还原酶抑制剂和抗炎剂预防痛风突发或减少痛风突发次数的方法
MX2007011927A (es) 2007-09-26 2009-03-26 World Trade Imp Export Wtie Ag Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa utiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas.
US20100311756A1 (en) 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
WO2011162390A1 (ja) 2010-06-25 2011-12-29 帝人ファーマ株式会社 徐放性高血圧および腎機能障害治療剤
NZ605562A (en) 2010-07-09 2013-11-29 Teijin Pharma Ltd Deuterated benzylbenzene derivatives and methods of use
AU2011299153B2 (en) 2010-09-10 2014-10-30 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat

Also Published As

Publication number Publication date
CA2812034C (en) 2018-10-23
EP2613780A1 (en) 2013-07-17
CN103298466A (zh) 2013-09-11
JP2013539747A (ja) 2013-10-28
US20120065215A1 (en) 2012-03-15
ES2532210T3 (es) 2015-03-25
HK1189170A1 (zh) 2014-05-30
JP5978216B2 (ja) 2016-08-24
US9107912B2 (en) 2015-08-18
WO2012033941A1 (en) 2012-03-15
KR20130097775A (ko) 2013-09-03
US20120065236A1 (en) 2012-03-15
US20120065207A1 (en) 2012-03-15
AU2011299153B2 (en) 2014-10-30
CN103298466B (zh) 2015-11-25
US8372872B2 (en) 2013-02-12
BR112013005792A2 (pt) 2016-05-03
CA2812034A1 (en) 2012-03-15
RU2013109380A (ru) 2014-10-20
EP2613780B1 (en) 2014-11-12
KR101797936B1 (ko) 2017-11-15
AU2011299153A1 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
BR112013005792A8 (pt) métodos para o tratamento concomitante de teofilina e febuxostat
BR112014009993A2 (pt) método para o tratamento de tumores do estroma gastrointestinal
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
MX2019001198A (es) Activadores de moleculas pequeñas de funcion de la enzima parkin.
GT201300258A (es) Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
PH12014500767A1 (en) Compositions for the treatment of dry eye
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
BR112015028879A2 (pt) derivados heterocíclicos
CR20140537A (es) Compuesto heterocíclico nitrogenado
EA201591612A1 (ru) ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ
GT201100118A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores hif
BR112014006587A8 (pt) Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
BRPI0712816B8 (pt) compostos de pirrolpirimidina e seus usos
PH12014500887A1 (en) Aminoalkyl-substituted n-thienyl benzamide derivative
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
IN2012DN01641A (https=)
BR112014011223A2 (pt) método de tratar uma doença proliferativa
BR112013001296A2 (pt) composições farmacêuticas e respectivo uso e métodos de tratamento de vertigem de diferentes origens, cinetose e distonia vascular vegetativa
WO2012158672A3 (en) Compounds for use in treatment of mucositis
GEP20166489B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
IN2012DN01642A (https=)
BR112013030051A2 (pt) método de tratar artigos com dióxido de carbono
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
BR112014000889A2 (pt) tratamento para hipoxia

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL